✓ Translated by DotMD AI Clinical Council Source: BMJ supportive & palliative care • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #38925875 ↗

Phase III Randomized Trial: General practitioner advance care planning knowledge and attitudes: ACP-GP cluster-randomised controlled trial

Original Paper Title: “General practitioner advance care planning knowledge and attitudes: ACP-GP cluster-randomised controlled trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The ACP-GP intervention did not improve GPs' knowledge and attitudes. Failure to detect an effect may stem from a ceiling effect, with GPs scoring high on baseline outcomes across groups. Questionnaires may require fine-tuning to accurately map their suggested role as potential barriers.
  • Study Design & Sample: Phase III Randomized Trial published in BMJ supportive & palliative care (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in BMJ supportive & palliative care (2024), this phase iii randomized trial evaluating human clinical outcomes investigated: Advance care planning (ACP) supports adults understanding and sharing their values, goals, and preferences regarding future medical care. Key clinical takeaway: The ACP-GP intervention did not improve GPs' knowledge and attitudes. Failure to detect an effect may stem from a ceiling effect, with GPs scoring high on baseline outcomes across groups. Questionnaires may require fine-tuning to accurately map their suggested role as potential barriers.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (BMJ supportive & palliative care, 2024-12-19; Phase III Randomized Trial; Rigor 82/100): The ACP-GP intervention did not improve GPs' knowledge and attitudes. Failure to detect an effect may stem from a ceiling effect, with GPs scoring high on baseline outcomes across groups. Questionnaires may require fine-tuning to accurately map their suggested role as potential barriers.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: crest-pro-health-cetylpyridinium-chloride → Rx: health-smart-vaporizing-chest-rub-menthol-and-camphor-and-eucalyptus-oil → Condition: personal-health-records → Condition: womens-health-checkup →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38925875: Phase III Randomized Trial: General practitioner advance care planning knowledge and attitudes: ACP-GP cluster-randomised controlled trial

3 of 3 Free Questions Remaining